Zhong Guo Jing Ji Wang·2026-02-05 08:27Core Viewpoint - Guangdong Jushi Chemical Co., Ltd. has been warned by the Shanghai Stock Exchange for violations in information disclosure, including inaccurate revenue accounting and failure to disclose related party transactions [1][2][3][4]. Group 1: Revenue Accounting Issues - The company engaged in circular trading through its subsidiary, Guangdong Guanzhen Technology Co., Ltd., leading to inaccurate revenue recognition [1][4]. - The subsidiary Anhui Jurun Trading Co., Ltd. sold isooctane to third parties without actual delivery, resulting in inflated revenue [1][4]. - The total inflated revenue for the first half of 2023 amounted to 156.81 million yuan, representing 8.32% of total revenue [5][7]. Group 2: Related Party Transactions - The company failed to disclose transactions with Guangzhou Kaishi Pharmaceutical Co., Ltd., which is controlled by the actual controller Chen Gang, constituting a related party transaction [1][2]. Group 3: Internal Control and Governance - The company exhibited poor internal control, including inadequate management of trade operations and financial processes, leading to discrepancies in revenue recognition [2][6]. - Key executives, including Chen Gang (Chairman), Zhou Kan (General Manager), and Wu Yang (CFO), were found responsible for these governance failures [3][6]. Group 4: Regulatory Actions - The Shanghai Stock Exchange issued a public reprimand against the company and its executives for the violations, including fines totaling 2.4 million yuan for the company and individual fines for the executives [8][7]. - The company has been ordered to correct its practices and has received a warning from the Guangdong Securities Regulatory Bureau [8].